First Trust Capital Management’s AEON Biopharma AEON Stock Holding History

First Trust Capital Management’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,240	Closed	-$3.79M	–	230
2022 Q4	$3.79M	Buy	5,240 +611	+13%	+$438K	0.2%	156
2022 Q3	$3.28M	Buy	4,629 +1,154	+33%	+$817K	0.16%	190
2022 Q2	$2.45M	Buy	+3,475	New	+$2.45M	0.17%	159

Other funds holding AEON

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $990M AUM 4.73% 1-Year Est. Return

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.42B AUM 0.61% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return

First Trust Capital Management's AEON Position: Q1 2023 in Review

First Trust Capital Management sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 5,240 shares — an estimated $3.79M sold.

First Trust Capital Management first reported a position in AEON in Q2 2022 and held it in 3 quarters. The position peaked at $3.79M in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

First Trust Capital Management reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
First Trust Capital Management sold 5,240 AEON Biopharma shares in Q1 2023, an estimated $3.79M.
First Trust Capital Management first reported a position in AEON Biopharma in Q2 2022 and held it in 3 quarters.
First Trust Capital Management's AEON Biopharma position peaked at $3.79M in Q4 2022.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on First Trust Capital Management's 13F filing for Q1 2023, filed 12 May 2023.